Loading patent…
AssigneeIonis Pharmaceuticals, Inc.
InventorsThazha P. Prakash, Punit P. Seth, Eric E. Swayze, Mark J. Graham
Estimating the term…
Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein C-III (ApoCIII). In certain embodiments, the ApoCIII targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting ApoCIII for use in decreasing ApoCIII to treat, prevent, or ameliorate diseases, disorders or conditions related to ApoCIII. Certain diseases, disorders or conditions related to ApoCIII include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.
A method of reducing expression of apolipoprotein C3 in a subject comprising administering a compound comprising a modified oligonucleotide and a conjugate group, or a pharmaceutically acceptable salt thereof, to a subject having familial chylomicronemia syndrome (FCS), wherein the modified oligonucleotide consists of 12 to 30 linked nucleosides, comprises a nucleobase sequence comprising a portion of at least 20 contiguous nucleobases complementary to an equal length portion of nucleobases 3533 to 3552 of SEQ ID NO:
A method of treating hypertriglyceridemia in a subject comprising administering to the subject having hypertriglyceridemia a compound comprising a modified oligonucleotide and a conjugate group, or a pharmaceutically acceptable salt thereof, wherein the modified oligonucleotide consists of 12 to 30 linked nucleosides, comprises a nucleobase sequence comprising a portion of at least 20 contiguous nucleobases complementary to an equal length portion of nucleobases 3533 to 3552 of SEQ ID NO:
A method of treating familial chylomicronemia syndrome (FCS) in a subject comprising administering to the subject having FCS a compound comprising a modified oligonucleotide and a conjugate group, or a pharmaceutically acceptable salt thereof, wherein the modified oligonucleotide consists of 12 to 30 linked nucleosides, comprises a nucleobase sequence comprising a portion of at least 20 contiguous nucleobases complementary to an equal length portion of nucleobases 3533 to 3552 of SEQ ID NO:
Dependencies are inferred from the claim text.